Shenzhen Salubris Pharmaceuticals (002294) Q2 2024 earnings summary

Executive summary

• Achieved revenue of ¥2.04 billion in H1 2024, up 21.28% year-over-year, with net profit attributable to shareholders at ¥344 million, up 1.92% year-over-year.

• Innovation-driven growth: new products contributed more to revenue, with two innovative drugs approved and launched in H1.

• R&D investment reached ¥460 million, accounting for 22.51% of revenue; sales expenses increased 44.24% year-over-year.

• Medical device revenue grew 49.62% year-over-year, with the segment beginning to turn profitable.

• No interim dividend, bonus shares, or capital increase from reserves planned for the half-year.

Financial highlights

• Operating income: ¥2.04 billion, up 21.28% year-over-year.

• Net profit attributable to shareholders: ¥344 million, up 1.92% year-over-year.

• Net profit excluding non-recurring items: ¥334 million, up 8.46% year-over-year.

• Operating cash flow: ¥533 million, up 50.81% year-over-year.

• Basic and diluted EPS: ¥0.31, up 3.33% year-over-year.

Outlook and guidance

• Continued focus on innovative drug development, with several products in late-stage clinical trials and multiple pipeline launches expected in coming years.

• Anticipates further growth in innovative product revenue share and ongoing expansion in chronic disease and specialty drug markets.